Paper Details

  1. Home
  2. Paper Details

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.

Author: ClarkDouglas, IlievHristo, KaspersStefan, Kinduryte SchorlingOna, LeeJisoo, ZwienerIsabella

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Empagliflozin 10 mg and 25 mg were well tolerated in patients with type 2 diabetes mellitus, confirming its established clinical safety profile. The study found that the incidence of adverse events was similar across treatment groups, except for a higher rate of genital infections with empagliflozin.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS: Pooled data from 20 trials were analyzed for patients with...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370973/

データ提供：米国国立医学図書館（NLM）

Empagliflozin: A Safe and Tolerable Option for Type 2 Diabetes

The world of diabetes research is a vast desert, and we're constantly seeking oases of effective and safe treatments. This research focuses on empagliflozin, a medication used to manage type 2 diabetes. The study employed a comprehensive approach, pooling data from 20 clinical trials, to assess the safety and tolerability of empagliflozin in patients with type 2 diabetes. The researchers analyzed data from patients who received either empagliflozin (10mg or 25mg) or a placebo.

The results indicate that empagliflozin, at both doses, is well-tolerated by patients with type 2 diabetes. The incidence of adverse events, including those that led to treatment discontinuation, was similar across all groups. The incidence of serious adverse events requiring hospitalization was also comparable between the empagliflozin and placebo groups.

Empagliflozin: A Promising Solution for Type 2 Diabetes

This study reinforces the established safety profile of empagliflozin and provides valuable information for healthcare professionals. The findings suggest that empagliflozin can be a safe and effective option for managing type 2 diabetes, offering patients a potential oasis in their journey to better health.

Empagliflozin: Considerations for Diabetic Patients

While empagliflozin appears to be generally safe and well-tolerated, it's important to remember that every individual's health journey is unique. If you are diagnosed with type 2 diabetes, it's essential to discuss treatment options with your doctor. They can help you determine the most appropriate treatment plan based on your specific needs and medical history.

Dr.Camel's Conclusion

This research reminds us that like a desert oasis, empagliflozin offers a safe and potentially effective respite for those navigating the challenging landscape of type 2 diabetes. It's crucial to work with your doctor to find the best oasis for your unique journey to better health.

Date :
  1. Date Completed 2021-02-08
  2. Date Revised 2022-02-10
Further Info :

Pubmed ID

32372290

DOI: Digital Object Identifier

PMC7370973

Related Literature

Article Analysis
・Side Effects of canagliflozin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.